MIST Stock — Milestone Pharmaceuticals Inc. Common Shares: Cash, EV, Pipeline

Share price

$0.92

Market cap

$114.0M

Cash

$170.6M

Enterprise value

$2.6M

Balance sheet

Cash	$170.6M
Debt	$59.2M
Net cash	$111.4M
Enterprise value	$2.6M
Basic shares	124.5M shares
Fully diluted shares	132.7M shares
Fully diluted market cap	$122.0M
Cash per share	$1.37

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MIST daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Etripamil NS	Phase 2	Paroxysmal Supraventricular Tachycardia	—
Jan 12 - Feb 23	Etripamil	Phase 3	Atrial Fibrillation	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

etripamil

Approved · Active Modality: small molecule (rapid-onset nasal spray)

Aliases CARDAMYST, TACHYMIST (EU trade name)

Target L-type calcium channel

Partnerships Corxel Pharmaceuticals (formerly Ji Xing Pharmaceuticals; China/Hong Kong/Macau/Taiwan license; NMPA NDA accepted January 2025 following Phase 3 JX02002); Everest Medicines (regional partner)

Indications

Paroxysmal supraventricular tachycardia (PSVT) (Approved)
Atrial fibrillation with rapid ventricular rate (AFib-RVR) (Phase 3)

Status note CARDAMYST (etripamil) nasal spray FDA approved December 12, 2025 for conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. EU MAA submitted November 2025 under trade name TACHYMIST. AFib-RVR: Phase 2 ReVeRA completed; FDA concurred on an sNDA pathway with a single pivotal Phase 3 study.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Etripamil
Lead indication	Atrial Fibrillation
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06716021	Phase 3	Recruiting	Sponsor	Milestone Pharmaceuticals Inc.	—	Atrial Fibrillation	—
NCT05763953	Phase 2	Recruiting	Sponsor	Milestone Pharmaceuticals Inc.	—	Paroxysmal Supraventricular Tachycardia	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Milestone Pharmaceuticals Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	7,833,336	+1,502,335	0.09%	2026-08-14
ADAR1 Capital Management	100,000	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MIST — Milestone Pharmaceuticals Inc. Common Shares